Guggenheim Maintains Neutral on Amgen, Raises Price Target to $435

Benzinga · 19h ago
Guggenheim analyst Vamil Divan maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $378 to $435.